Ally Bridge Group’s Dianthus Therapeutics DNTH Stock Holding History

Ally Bridge Group’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-80,584	Closed	-$1.46M	–	30
2025 Q1	$1.46M	Sell	80,584 -25,850	-24%	-$570K	1.32%	23
2024 Q4	$2.32M	Buy	+106,434	New	+$2.74M	1.99%	24
2024 Q2	–	Sell	-216,968	Closed	-$6.51M	–	26
2024 Q1	$6.51M	Buy	+216,968	New	+$4.72M	3.62%	14

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ally Bridge Group's DNTH Position: Q2 2025 in Review

Ally Bridge Group sold out of Dianthus Therapeutics (DNTH) in Q2 2025, closing a stake of 80,584 shares — an estimated $1.46M sold.

Ally Bridge Group first reported a position in DNTH in Q1 2024 and held it in 3 quarters. The position peaked at $6.51M in Q1 2024. 102 funds tracked by Wall St. Rank hold DNTH as of Q2 2025.

Ally Bridge Group reported no remaining Dianthus Therapeutics position as of Q2 2025 after selling out during the quarter.
Ally Bridge Group sold 80,584 Dianthus Therapeutics shares in Q2 2025, an estimated $1.46M.
Ally Bridge Group first reported a position in Dianthus Therapeutics in Q1 2024 and held it in 3 quarters.
Ally Bridge Group's Dianthus Therapeutics position peaked at $6.51M in Q1 2024.
102 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2025.

Based on Ally Bridge Group's 13F filing for Q2 2025, filed 14 Aug 2025.